LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia

Coronavirus Disease 2019 Clinical Trial

Official title: A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV, & COVID-19 and LIAISON PLEX Respiratory (RSP) Flex Assays in Symptomatic Patients in Australia

Status Not yet recruiting

Clinical Trial Summary

To establish the relative accuracy of the LIAISON® NES Flu A/B, RSV & COVID-19 assay for viral nucleic acid targets from professionally collected or patient self-collected dry nasal (NS) swabs and to establish the relative accuracy of the LIAISON PLEX® RSP Flex assay from NS and nasopharyngeal swabs (NPS) in applicable transport media from human patients exhibiting clinical signs and symptoms of a respiratory tract infection.

Clinical Trial Description

This study is a clinical evaluation of two investigational devices on the same patient specimens:

• The LIAISON® NES FLU A/B, RSV & COVID-19 assay used for the detection and identification of influenza A, influenza B, RSV and SARS-CoV-2 on the LIAISON® NES system, developed by DiaSorin Molecular

• The LIAISON PLEX® RSP Flex assay used for the detection and identification of 19 common respiratory pathogens, including 14 viral and 5 bacterial targets on the LIAISON PLEX® system, developed by Luminex Corporation (a subsidiary of DiaSorin)

This study will utilize untrained operators to perform investigational device testing on the LIAISON NES platform, and as such instrument or assay-specific training will not be provided beforehand. Sites will receive the necessary protocols and instructions for use required to implement the study protocol. Testing on the LIAISON PLEX® platform will be performed by trained operators. Study staff will receive training on the device prior to the start of testing. The diagnostic accuracy of the LIAISON® NES FLU A/B, RSV & COVID-19 assay will be evaluated using dry NS specimens prospectively collected from patients who meet the study inclusion criteria. The diagnostic accuracy of the LIAISON PLEX® RSP Flex assay will be evaluated using NS and NPS specimens prospectively collected from patients who meet the study inclusion criteria and stored in the applicable transport media. Performance of the LIAISON® NES FLU A/B, RSV & COVID-19 and LIAISON PLEX® RSP Flex assays will be compared to one or more US FDA-cleared molecular assays, or as required by the local regulatory body.

Approximately 600-1000 prospective specimens will be tested using the LIAISON® NES FLU A/B, RSV & COVID-19 and LIAISON PLEX® RSP Flex assays, with a goal to obtain approximately 50 comparator method confirmed positives per target for influenza A and SARS CoV-2 and 30 comparator method confirmed positives per target for influenza B and RSV. The study is estimated to be conducted for approximately 3 months and should cover the length of the flu season, as appropriate. ;

Related Conditions & MeSH terms

• Adenovirus
• Bordetella Parapertussis Infection
• Chlamydia Pneumonia
• Communicable Diseases
• Coronavirus Disease 2019
• Coronavirus Infections
• COVID-19
• Enterovirus
• Infections
• Influenza A
• Influenza Type B
• Influenza, Human
• Mycoplasma Pneumonia
• Paramyxoviridae Infections
• Pneumonia
• Pneumonia, Mycoplasma
• Respiratory Syncytial Virus (RSV)
• Respiratory Tract Infections
• Whooping Cough

• NCT number: NCT06392451
• Study type: Interventional
• Source: DiaSorin Molecular LLC
• Contact: Rachel Behounek, PhD
• Phone: 512-336-3554
• Email: rbehounek@luminexcorp.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 6, 2024
• Completion date: October 31, 2024